Internationally renowned Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital acquires Elekta’s Leksell Gamma Knife Icon
The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), among the world’s largest and most prestigious cancer centers, has acquired Elekta’s Leksell Gamma Knife® Icon™, the company’s latest generation stereotactic radiosurgery system for the brain.
With the option to use frameless (multi-session) or traditional frame-based treatments, Leksell Gamma Knife Icon offers greatly enhanced flexibility in how clinicians deliver stereotactic radiosurgery. Frameless, mask-based therapy provides the opportunity to expand the range of patients who could benefit from Gamma Knife radiosurgery.
“As a multidisciplinary neuro-oncology team at NKI-AVL we have been impressed by the superior dose distribution that can be achieved by Gamma Knife technology,” says Prof. Marcel Verheij MD PhD, Chair Department of Radiation Oncology, NKI-AVL. “This is particularly important for the increasing numbers of patients here who present with multiple small intracranial metastases and a relatively good prognosis. Preserving cognitive functions and quality-of-life in these patients is of utmost importance. The integration of a cone beam CT in Icon adds a new and exciting dimension to the system and perfectly fits in our concept of image-guided high precision radiotherapy. In addition, Leksell Gamma Knife Icon will allow frameless solutions and offers the opportunity to apply fractionated radiotherapy, further contributing to a more personalized treatment approach.”
NKI-AVL’s Gamma Knife Icon system is expected to be operational by August 2016. Equipped with an array of Elekta linear accelerators, planning solutions and ancillary radiotherapy technology, NKI-AVL – also a member of the Elekta Atlantic Consortium (MRI-guided radiation therapy) – further strengthens its reputation as a radiation therapy center of excellence with the acquisition of Icon.
Gamma Knife Icon is the sixth generation of the company’s Leksell Gamma Knife® system, a technology that has been in use worldwide and continually evolving since the 1980s. The NKI-AVL system is the latest of several orders since Gamma Knife Icon was CE marked in June and received 510(k) clearance in August this year.
For more information on Leksell Gamma Knife Icon, visit www.careforthebrain.com
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, Email: email@example.com
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, Email: firstname.lastname@example.org
Time zone: EST: Eastern Standard Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com Twitter: @Elekta.